Table 5 The secondary KRAS mutation rate stratified by the duration of anti-EGFR therapy in the chemotherapy plus cetuximab subgroups of Group B and Group C.
Group | Wild type | Mutation type | Total | Rate |
|---|---|---|---|---|
The subgroup with an anti-EGFR therapy duration of less than 10 months | 16 | 1 | 17 | 5.9% (1/17) |
The subgroup with an anti-EGFR therapy duration of more than 10 months | 6 | 2 | 8 | 25.0% (2/8) |
Total | 22 | 3 | 25 | 12.0% (3/25) |
